What are you searching for?

Sign in
People

Dean Gregory Named to Cerus Corporation’s Board of Directors

New board member spent 15 years at Baxter International.

By: Michael Barbella

Managing Editor

Cerus Corporation has appointed Dean Gregory to its Board of Directors.

Gregory has spent more than 30 years as a leader in the global blood transfusion and cell therapy industry, with broad experience across commercialization, product development, supply chain and manufacturing. For the last decade, he was president of Global Commercial Operations, Med Tech for Fresenius Kabi, the role from which he retired earlier this year.

“We are very pleased to welcome Mr. Gregory to Cerus’ Board of Directors,” Cerus Board Chair Daniel Swisher said. “Mr. Gregory brings a wealth of experience and expertise across the global transfusion medicine market, having led the commercial organization of one of the major suppliers for blood centers and hospitals in this space. We believe that his deep and broad knowledge of Cerus’ customer base will be instrumental as the Company continues to focus on expanding the reach of the INTERCEPT Blood System in existing and new geographies, as well as advancing the INTERCEPT Red Blood Cell program. Mr. Gregory’s history of operational leadership will also be valuable to Cerus’ ongoing initiatives to expand manufacturing capacity in line with demand. We look forward to benefiting from the insights Mr. Gregory will provide for the company.”

Prior to his role at Fresenius Kabi, Gregory served as senior vice president of Global Commercial Operations at Fenwal Inc., subsequent to its purchase by the Texas Pacific Group from Baxter International. During his time at Fenwal, he was responsible for the global commercial team that delivered the strong revenue growth that ultimately led to Fenwal’s acquisition by Fresenius Kabi in 2012. Before that, Gregory worked at Baxter International for more than 15 years, assuming roles with increasing responsibility across commercial, business development and strategy functions, primarily in the transfusion medicine and cell therapy space.

“I am excited to be joining the Board of Directors at Cerus at a time of strong growth expectations for the company’s pathogen inactivation technology,” Gregory stated. “I have a longstanding connection to Cerus and the INTERCEPT Blood System, and I am thrilled to be able to contribute in this new way. My entire career has been focused on supporting patient access to safe blood products, and I believe strongly in the company’s mission and in the Cerus team that has worked so hard over the last two decades to establish this new standard of care for transfusion medicine.”

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, Calif., the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and U.S. Food and Drug Administration approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the United States. Also in the United States, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. 

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

 

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters